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SUMMARY 
.4 new fluorogenic substrate, 4 methylumbelliferyl~-~-6-sulphogalactoside, was used for the 
assay of galactose-6-sulphate sulphatase activity in chorionic villi, cultured villus cells, and 
amniocytes. The fluorometric assay is much more convenient than the conventional assay 
iising radiolabelled, sulphated oligosaccharides. Both types of substrate were used in the 
prenatal diagnosis of three pregnancies at risk for Morquio type A disease using amniocytes. 
These enzyme tests, as well as electrophoresis of glycosaminoglycans in the amniotic fluid, 
indicated affected fetuses in two pregnancies and a non-affected fetus in one. 
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INTRODUCTION 
Prenatal diagnosis of Morquio disease type A (Mucopolysaccharidosis type IV A 
iMPS IV A)) has been made by demonstrating the deficiency of N-acetylgalactosa- 
inine-6-sulphate sulphatase (Figura er al., 1982). Subsequently it was shown that 
most types of MPS, including MPS IV A, can also be demonstrated prenatally by 
electrophoresis of glycosaminoglycans (GAG) in amniotic fluid (Mossman and 
Patrick, 1982). 
The defective sulphatase in MPS IV A has activity towards oligosaccharides with 
a terminal N-acetylgalactosamine-6-sulphate (GalNAc-6s) (Matalon et at., 1974; 
Singh et al., 1976) or galactose-6-sulphate (Gal-6s) (Glossl and Kresse, 1982; 
'Yukata et al., 1982), which explains the defect in the catabolism of both chondroitin- 
ci-sulphate and keratan sulphate in MPS IV A. The commonly used method for the 
diagnosis of MPS IV A is the technically difficult GalNAc-6S sulphatase assay 
iising a radiolabelled trisaccharide (Glossl et al., 1981). We have synthesized 
4-methylumbelliferyl (4MU)-6-sulphogalactoside and have shown that this is an 
excellent substrate for the assay of Gal-6S sulphatase in cultured fibroblasts and in 
leukocytes (Van Diggelen et al., 1990). In this assay, the fluorochrome 4MU is 
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released after the successive action of Gal-6S sulphatase and endogenous p- 
galactosidase which is present in large quantities in the cell types investigated. In this 
report we describe optimal conditions for the assay of Gal-6S sulphatase and 
the ranges of activity in chorionic villi (CV), cultured CV cells and amniocytes, and 
in fetal liver, brain, and muscle. This fluorometric enzyme assay was applied in 
retrospective as well as in prospective prenatal analyses in pregancies at risk. 
PATIENTS AND METHODS 
Prenatal analyses were performed in the pregnancies of three mothers each of whom 
had a previous child with MPS IV A. Amniotic fluid cells from pregnancy 1 were 
kindly made available to us by Dr G. T. N. Besley (Edinburgh) for retrospective 
analysis. Amniocentesis in the 17th week of pregnancies 2 and 3 was performed in 
Warsaw, where also chromosome analyses were done; part of the fluid was sent to 
Rotterdam for cell cultivation and biochemical analysis. 
Chorionic villi were obtained by transcervical aspiration from pregnancies at 
risk for chromosomal disorders or after elective termination of pregnancy. After 
dissection and microscopic selection the villi were washed in saline and stored at 
- 70°C until use. Cells from minced and collagenase-treated villi were cultured In 
Ham’s F12 and after the beginning ofcell growth in Ham’s F10 both with 5 per cent 
FCS and with 4 per cent Ultroser G (IBF, France). 
Amniotic fluid cells and fibroblasts were cultivated in Ham’s F10 medium with 20 
and 15 per cent FCS, respectively; they were harvested 7 days after the previous 
trypsinization and homogenized by sonication in water. Chorionic villi and other 
fetal tissues were homogenized iin a Potter tube before sonication. 
For the standard Gal-6S sulphatase assay, the cell or tissue homogenate was 
centrifuged for 10 min at 12 000 rpm and the supernatant was dialysed overnight at 
4°C against 0.01 mol/l sodium acetate buffer, pH 6.0, containing 0.1 mol/l sodium 
chloride. The substrate, 4MU-Gal-6S, was synthesized as described by Van 
Diggelen et af. (1990); it is commercially available (Melford Laboratories Ltd, 
Ipswich, U.K.). The reaction mixture (30 pl) consisted of 10 p1 of dialysed super- 
natant containing 20pg of protein and 2 0 4  of 1 mM 4MU-Gal-6S in 0.1 mol/l 
sodium acetate buffer, pH 4.3, with 0.1 mol/l sodium chloride. After incubation for 
17h  at 3792, the reaction mixture was supplemented with lop1 supernatant 
from MPS IV A fibroblasts and 2 pl of 2 mol/l sodium phosphate buffer, pH 4.3, 
and incubation was continued for 2 h  at 37°C to complete the hydrolysis of 
4MU-P-galactoside. 
The reaction was stopped by tlhe addition of 200 p1 of 0.5 mol/l sodium carbonate 
buffer, pH 10.7, and the fluorescence of free 4MU was measured in a Fluoroscan 
fluorometer (Titertek). The measurement was corrected using a blank value 
obtained by incubating the complete reaction mixture in the presence of 0.1 mol/l 
sodium phosphate buffer, pH 4.3, which completely inhibits Gal-6S sulphatase (Van 
Diggelen et af., 1990). 
Protein was determined using the BCA method (Smith et al., 1985). One- and two- 
dimensional electrophoresis of GAG was performed as described before (Mossman 
and Patrick, 1982). 
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Figure 1. Kinetic properties of galactose-6-sulphate sulphatase in chorionic villi (O) ,  cultured chorionic 
villus cells (0), and arnniocytes ( A ) .  (A) Protein dependency; (B) time course; (C) Lineweaver-Burk 
plot, S =  substrate concentration (4MU-Gal-6s; mM), V =  specific activity (nmol/l7 h-'/rng protein); 
(D) pH dependency 
RESULTS 
Enzyme assay conditions 
Various conditions for the assay of Gal-6S sulphatase activity in cultured cells and 
i n  fetal tissues were investigated. The results for cultured amniocytes and CV cells 
and for uncultured CV are shown in Figure 1. Similar results have been obtained for 
cultured fibroblasts (Van Diggelen et al., 1990) and for fetal tissues (liver, brain, 
muscle; not shown). The enzymatic reaction proceeded almost linearly with the 
amount of cellular protein (up to 2Opg) in the incubation mixture and with the 
incubation time, after a lag time of 30 min, up to 17 h. The K ,  for all cell types and 
tissues was estimated as 7 mM; the optimum pH in the cultured cells and in CV was 
pH 4.5. At pH 7.0 or higher, slight activity was only found in CV; this suggests that 
neutral sulphatases do not interfere in the assay. Gal-6S sulphatase activity in the 
centrifuged CV honiogenate is completely inhibited by 0.05 mol/l phosphate, which 
excludes interference of phosphate-resistant sulphatases such as arylsulphatase C. 
Eiased on these results, standard conditions were chosen for the enzyme assay in all 
cell types and tissues as described in Patients and Methods. A substrate concen- 
tration (0.67 mmol/l) far below the K ,  value was chosen for practical reasons (see 
Discussion). 
The ranges of Gal-6S sulphatase activity in fetal cells and tissues were established 
using the standard assay conditions and were compared with those in cultured skin 
fibroblasts of controls and of MPS IV A patients (Table 1). The Gal-6S sulphatase 
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Table 1. Galactose-6-sulphate sulphatase activity in fetal cells 
and tissues 
Cells or 
tissue 
Enzyme activity 
(nmol/l7 h/mg protein) 
Controls* Morquio A 
Skin 
fibroblasts 
Amniotic fluid 
cells 
Cultured chorionic 
villus cells 
Chorionic 
villi 
Fetal liver 
Fetal brain 
Fetal muscle 
38.9 (k 13.8) 
(n = 25) 
21.6 (k 5.3) 
13.2-32.9 
(n=21) 
19.9-78.8 
22.9 (k4.1) 
17.7-29.9 
(n= 19) 
12.6 (k 3.9) 
8G20.3  
(n=21) 
36-9.4 (n=3) 
4.2-5.9 (n = 3) 
8.5-1 5-0 (n = 3) 
0.35(+_0.18) 
0.03-0.60 
(n = 8) 
0.2; 1.0 
(n = 2) 
(see Table 2) 
*Mean & SD and ranges. 
?Affected fetus diagnosed in 1980 (Figura et al., 1982). 
activities in amniocytes and cultiired CV cells are approximately half the activity in 
fibroblasts, whereas the activity in (uncultured) CV is about one-third of the fibro- 
blast level. These levels of activity can be measured with high accuracy and are far 
above the very low levels which are found in fibroblasts of MPS IV A patients (1 per 
cent or less of the level in controlis). 
Gal-6S sulphatase also has considerable activity in fetal liver, brain, and muscle. 
even after storage for 4-10 years at - 70°C. In contrast, very low activity was shown 
in the tissues of a fetus with MPS IV A disease, i.e., less than 3 per cent of the mean 
activity in the controls (Table 1); a reference enzyme (B-galactosidase) had normal 
activity in these tissues (data not shown). 
In the present assay, the first incubation period of 17 h was followed by a period of 
2 h in which Gal-6S sulphatase was inhibited and the remaining 4MU-/?-galactoside 
was hydrolysed by extra supplied P-galactosidase (see Patients and Methods). 
Omission of the latter step led to an apparent reduction of Gal-6S sulphatase activity 
of 0-10 per cent for cultured amniocytes and CV cells, 5-20 per cent for uncultured 
CV, and 20-50 per cent for the few samples of fetal tissue tested (data not shown). 
Prenatal diagnosis 
Table 2 shows the results of prospective and retrospective studies of three preg- 
nancies at risk for MPS IV A. Skin fibroblasts of the probands and their parents 
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Table 2.  Galactose-6-sulphate sulphatase activity in 
amniotic fluid cells from three pregnancies at risk for 
Morquio disease type A 
~~ ~~ 
MU-Gal-6S sulphatase 
(nmol/l7 h/mg protein) 
Amniotic fluid cells 
Pregnancy 1 
Pregnancy 2 
Pregnancy 3 
Controls (range) 
Fibroblasts 
Family 2: 
Affected child 
Mother; father 
Family 3: 
Affected child 
Mother; father 
Controls (range) 
1 .O 
11.6 
0.2 
12433 .2  
(n=21) 
0.09 
14.3; 19.8 
0.00 
19.0; 12.5 
19.9-78.8 
(n = 25) 
were investigated and showed a profound deficiency of Gal-6S sulphatase activity in 
the patients and a reduced level in the four obligate heterozygous parents (families 2 
and 3). 
In pregnancy 1, the diagnosis of an affected fetus was made following the demon- 
stration by one-dimensional electrophoresis of an abnormal GAG pattern in the 
amniotic fluid and by the deficiencies of Gal-6S sulphatase and GalNAc-6S 
sulphatase in the cultured amniocytes using radiolabelled substrates (Drs D. 
Broadhead and G. Besley, Edinburgh). In retrospect, we have confirmed the 
deficiency of G a l 6  sulphatase in these amniocytes with the 4MU Gal-6S substrate; 
the level of residual activity was less than 2 per cent of controls. In the second 
pregnancy, MPS IV A was excluded by finding a normal pattern in the electro- 
phoresis of  GAG in amniotic fluid and a reduction of GalNAc-6S sulphatase (B. 
Poorthuis, Leiden) to a level which suggested heterozygosity. Subsequent testing of 
these cells, using the fluorometric assay, confirmed the diagnosis of a heterozygous 
fetus. The child was recently born and is healthy. In the third pregnancy at risk, 
the fluorometric test was applied for prospective prenatal diagnosis. A complete 
deficiency of Gal-6S sulphatase in the amniocytes indicated unequivocally that 
the fetus was affected, although two-dimensional electrophoresis had not shown 
clear evidence of keratan sulphate in the amniotic fluid. One-dimensional 
electrophoresis, however, showed a band running ahead of chondroitin sulphate in 
the position of keratan sulphate. When, 3 weeks after amniocentesis, the diagnosis 
of  an affected fetus was reported, the pregnancy had already been terminated 
because of trisomy 21; no tissues or cells had been stored for confirmatory enzyme 
simdies. 
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DISCUSSION 
We have recently reported the synthesis of 4MU-Gal-6S and its use in the diagnosis 
of MPS IV A in patients and carriers, using cultured fibroblasts and leukocytes 
(Van Diggelen er al., 1990). The: investigations described here show that the fluoro- 
genic substrate is similarly effective in the assay of Gal-6S sulphatase in cultured 
amniocytes, CV cells, uncultured CV, and several (fetal) tissues. 
Gal-6S sulphatase activity in CV and amniocytes is lower than in fibroblasts, but 
it is sufficiently high for accurate measurement in small amounts of material. In the 
present investigations, a sub-optimal substrate concentration was used because of 
the limited amount of substrate available in the early stage of the studies; the enzyme 
activity may be considerably increased by raising the substrate concentration to a 
value above the K,. The measurement of true Gal-6S sulphatase activity depends 
on the complete hydrolysis of the desulphated, intermediate reaction product 
4MU-Gal. This is largely (i.e., 80-100 per cent) accomplished by endogenous D- 
galactosidase in CV and amniocytes; to guarantee complete release of 4MU, after 
stopping the sulphatase action, a second incubation may be performed for 2 h with 
additional P-galactosidase. The specificity of the present assay for Gal-6S sulphatase 
activity is demonstrated by the complete absence of activity in fibroblasts and 
amniocytes ofpatients. For CV, such direct proof of the specificity of the test has not 
been possible because defective CV have so far not been available. Arylsulphatase C ,  
which has high activity in CV (in contrast to fibroblasts and amniocytes), might be 
anticipated as a source of interference in any sulphatase assay (Kleijer et al., 1984; 
Fensom et al., 1988). However, its inactivity toward the substrate was shown by pH 
dependence and phosphate inhibition studies. 
Prenatal diagnosis for MPS I[V A has not been reported after CV sampling, but 
several prenatal analyses have been made after amniocentesis: e.g., in London/ 
Edinburgh 12 pregnancies at irisk were tested with four affected fetuses and in 
Rotterdam five cases with three affected fetuses. In all of the affected pregnancies 
from London/Edinburgh and in the present case 3 (Table 2), an abnormal GAG 
pattern in the amniotic fluid was clearly shown by one-dimensional electrophoresis 
whereas two-dimensional electrophoresis failed to separate keratan sulphate from 
the normally occurring constil uent chondroitin sulphate. In the remaining two 
affected cases from Rotterdam, two-dimensional electrophoresis showed an abnor- 
mally large spot at or near the position of chondroitin and keratan sulphate. These 
results confirm the suggestion by Mossman and Patrick (1982) that some difficulty 
might be experienced in the interpretation of the Morquio two-dimensional electro- 
phoresis pattern and that a better resolution might be obtained by  one-dimensional 
electrophoresis. 
GAG electrophoresis is a vailuable ancillary method for prenatal diagnosis of 
MPS IV A disease if amniotic fluid is the available material for study. However, 
since CV sampling allows a safe and reliable prenatal diagnosis for many disorders 
already in the first trimester (K'leijer, 1986) this method has become the method of 
choice whenever possible. The fluorometric assay of Gal-6S sulphatase described 
provides a simple and sensitive: method for prenatal diagnosis of MPS IV A; its 
reliability was shown here by the prospective and retrospective analyses of amniotic 
fluid cells from three pregnancies at risk. Our studies also suggest that this enzyme 
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assay should provide an efficient and reliable method of prenatal diagnosis in the 
first trimester of pregnancy by direct analysis of CV and cultured CV cells. 
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